Nautilus Biotechnology (NAUT) Q3 2026 earnings review
Nautilus validates its cancer protein tests, but cash burn rises
Nautilus Biotechnology, a developer of machines for studying human proteins, proved its tests work on cancer proteins while its cash burn climbed. Chief executive Sujal Patel said the cancer test results matched its first brain protein test, and the firm joined a federal research group worth up to $6 million. However, operating expenses rose 10% from a year ago to $17 million, ending six straight quarters of cost reductions.
| Revenue | $0.23M up from $0.19M last quarter |
|---|---|
| Operating expenses | $16.9M +10% from a year ago |
| Cash and investments | $114.3M $14.8M burned in Q3 by our math |
| Instrument launch outlook | Unchanged planned availability in mid-2027 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because scientific progress on targeted protein tests was offset by rising cash usage ahead of a planned fundraising. By our math, quarterly cash burn reached $15 million, and beating the $155,000 quarterly revenue pace implied by the full-year plan only reflects steady grant billing rather than commercial demand.
The question now is whether the shift to targeted cancer tests is a smart focus on a unique tool or a forced retreat from the larger general protein market. If customer demand drives it, paid service projects and early-2027 machine pre-orders will build quickly; if not, service revenue will stay near $26,000. Fourth-quarter test machine placement and early-2027 pre-order numbers will decide.
🐂 Bull Case
Cancer Protein Tests Match Brain Test Performance
Nautilus is building the Voyager machine to measure proteoforms, which are the different chemical shapes a single human protein can take. After delaying its general protein product last quarter, the company shifted its engineers toward targeted protein tests and aimed to prove its method works beyond its first brain protein test, Tau.
"Our proteoform expansion initiative is on-track, with early oncology assay results that demonstrate the performance we established with Tau is repeatable across additional targets," chief executive Sujal Patel said. The life sciences group presented first cancer test data, including a protein called AKT1, "showing a performance profile matching Tau and supporting platform extensibility". It also published its measurement method in the journal Nature Methods.
This matters because the Tau test only works on brain tissue, which limits how many labs can use it today. Cancer tests use more common lab samples, so matching Tau's performance keeps the plan for twenty tests by mid-2028 alive.
What to watch: entry of the AKT1 cancer test into the early access service programme in late 2026. Hitting that schedule would show the new test is ready for outside customer samples.
Federal Research Consortium Adds Up to $6 Million
Because Nautilus will not sell its Voyager machines until mid-2027, it relies on research grants to fund joint work and bring in early cash. Until now, its only grant came from The Michael J. Fox Foundation for Parkinson's disease research.
After the quarter ended, the Seattle-based company joined SEEDS, a four-year research group funded by the US federal health agency ARPA-H. Nautilus expects to receive up to $6 million to "deploy its Voyager Platform TM to measure proteoforms driving Alzheimer’s disease and cancer". Meanwhile, third-quarter grant revenue rose to $208,000 from $180,000 in the second quarter.
The federal award is five times the size of the $1.2 million Parkinson's grant, so it gives outside validation and non-dilutive funding. However, the company noted that the SEEDS funding "may be reduced, delayed or terminated". Beating the $155,000 revenue pace implied by the full-year plan only shows that grant work ran steadily this quarter.
What to watch: the timing of the first cash payment and revenue from the SEEDS consortium in 2027. Steady quarterly payments would offset lab costs without issuing new shares.
🐻 Bear Case
Cash Burn Rises Ahead of Planned Fundraising
Nautilus funds its research from a shrinking pile of cash and investments, and it plans to raise debt or equity before mid-2027. Keeping quarterly cash usage under control is critical because higher spending shortens its cash runway and increases the money it must raise.
Cash, cash equivalents and investments dropped to $114.3 million at the end of September from $129.2 million in June. By our math, the developer burned $14.8 million during the third quarter, up from $14.2 million in the second quarter and $11.0 million a year ago.
- Third-quarter cash burn: $14.8 million by our math, the fourth straight quarterly increase
- Cash and investments remaining: $114.3 million, down 32.1% from $168.5 million a year ago
- Nine-month operating cash outflow: $40.1 million, up from $38.3 million last year
- Third-quarter interest income: $1.2 million, down 38.4% from $1.9 million a year ago
Cash usage is rising because operating costs turned higher while a smaller cash balance earns less interest income. At the third-quarter burn rate of $14.8 million, the $114.3 million balance covers about 7.7 quarters by our math, leaving little room for cost overruns as machine manufacturing begins.
What to watch: fourth-quarter cash usage against the $114.3 million balance. Another step up in spending would pressure the company to raise capital sooner.
Operating Costs Rise After Six Quarters of Cuts
When Nautilus shifted engineers to targeted protein tests last quarter, it said it would fund the move by shifting staff rather than spending more. For the prior six quarters, total operating expenses had fallen compared with a year earlier following a 2025 staff reduction.
In the third quarter, total operating expenses rose 9.5% from a year ago to $16.9 million, and net loss widened 15.2% to $15.6 million. Selling, general and administrative costs — overhead and sales staff — climbed 15.4% to $6.8 million, while research and development costs grew 5.9% to $10.2 million. Nautilus attributed the increase to "higher laboratory and professional services and higher salaries and related benefits expense".
Because revenue is only $234,000, expense ratios in percentage points of revenue do not measure cost discipline yet. Instead, the dollar increase shows that shifting staff did not stop total spending from rising again. By our math, the prior full-year cost ceiling still allows fourth-quarter operating expenses to jump by up to 58.9% from a year ago.
What to watch: fourth-quarter operating expenses against the $16.9 million third-quarter level. A further jump would confirm that pre-launch commercial and lab hiring is lifting the permanent cost base.
Early Access Services Barely Cover Direct Costs
Nautilus runs an Iterative Mapping Early Access Program where outside researchers pay the company to test protein samples in its own lab. This service is meant to build customer demand before machine pre-orders open in early 2027.
Service revenue reached $26,000 in the third quarter, up from $10,000 in the second quarter, while the direct cost of delivering those services was $24,000. Across the first nine months of 2026, service revenue totaled $36,000 against $39,000 in direct service costs, and the press release gave no count of active paying customers.
Running customer samples is a way to prove the technology rather than a profit engine today, but $26,000 of sales shows that paid commercial testing remains tiny. With the Tau test limited to brain tissue samples, near-term customer demand depends on getting the new cancer tests into the lab.
What to watch: whether the company discloses the number of paying early access customers on the conference call or in the quarterly filing. Continued silence would indicate that paid sample volume remains just a handful of projects.
Risks this quarter didn't answer
Three standing risks around the delayed general protein test, manufacturing supply, and customer budgets received no new numbers or timelines in the third-quarter release.
- Broadscale general protein test: not mentioned in the release after losing its 2027 launch target last quarter; the quarterly filing will show if it still lacks a target date.
- Single-source suppliers for Voyager parts and reagents: no update in the release; any supply bottleneck would appear in the quarterly filing's risk disclosures.
- Academic and non-profit customer budget delays: not updated in the release; conference call commentary will show whether university lab funding is still slowing $1 million machine buying decisions.
💲 Other KPIs
Property and equipment purchases rose to $1.45 million in the third quarter by our math, up from $0.45 million in the second quarter and $0.51 million in the first quarter. Nine-month equipment spending more than doubled to $2.41 million from $1.03 million a year ago, directly increasing cash burn as the firm builds lab capacity.
Employee stock award expense was $1.29 million in the third quarter by our math, down 13.6% from $1.50 million a year ago. Across the first nine months of 2026, stock compensation fell 29.1% to $3.81 million from $5.37 million, which held down reported operating expenses without saving any cash.
The share count rose 0.7% from 126.3 million a year ago and 0.1% from the second quarter. Stock option exercises and employee stock purchases brought in $1.38 million of cash over the first nine months, indicating the proteomics developer has not yet tapped its $125 million share sale facility.
🔮 Guidance
Unchanged. Patel reiterated "planned instrument availability in the middle of 2027". The company previously pushed instrument shipments to mid-2027 after originally targeting a late 2026 commercial launch. Hitting the mid-2027 target requires placing a test machine before year-end and opening pre-orders in early 2027.
Unchanged. The life sciences group still plans to deliver twenty targeted protein tests through the middle of 2028, starting with Tau, AKT1, and two additional cancer tests in 2027. Keeping this schedule is essential because the machine launch depends on having multiple cancer and brain tests ready for customers.
❓ Key Questions
Did Nautilus keep its 2026 revenue and expense targets?
On the second-quarter call, the company forecast about $0.5 million in full-year revenue and operating expense growth below 10%. The third-quarter release omitted numerical targets, and nine-month revenue of $424,000 is already near the $500,000 mark.
How many paying early access customers are active today?
Service revenue rose from $10,000 to $26,000 this quarter, but direct service costs were $24,000. Without customer counts or repeat order numbers, investors cannot tell if early lab trials are converting into future machine buyers.
When will the broadscale general protein test launch?
After pulling its 2027 launch target last quarter, the company did not mention the broadscale programme in this release. That test targets the largest established proteomics market, so leaving it undated limits long-term sales potential.
When will Nautilus raise cash, and in what form?
Quarterly cash burn reached $14.8 million by our math, leaving $114.3 million on the balance sheet. Management plans to raise debt or equity before mid-2027, and the structure will determine how much dilution shareholders face.